Navigation Links
Regulus Files Registration Statement for Proposed Initial Public Offering
Date:8/20/2012

LA JOLLA, Calif., Aug. 20, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company founded by Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.  All shares of the common stock to be sold in the offering will be offered by Regulus.  The number of shares to be offered and the price range for the offering have not yet been determined.

Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets are acting as joint book-running managers for the offering.  Needham & Company, LLC and Wedbush PacGrow Life Sciences are acting as co-managers.  The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48th Floor, New York, NY 10020, Telephone: (800) 542-0970; from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, Telephone: (631) 274-2806, Fax: 631-254-7140); or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square New York, NY 10036, Telephone: (800) 414-3627, E-mail: bmoprospectus@bmo.com.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Regulus

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases.

 


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
2. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
4. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date
5. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case
6. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
7. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
8. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
9. Ronald L. Chez Files Amended 13D and Letter to the Board
10. China Cord Blood Corporation Files its Annual Report on Form 20-F
11. Registration now open: 2012 Regional, State, and Local Initiatives in Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... YORK , April 28, 2016 ... acceleration company reports the Company,s CEO  was featured ... titled Accelerators Enter When VCs Fear To Tread: ... Science Leader magazine is an essential ... for everything from emerging biotechs to Big Pharmas. ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut ... innovative, growing companies, today announced the launch of VentureClash , a $5 ... , “VentureClash looks to attract the best early-stage companies here in ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... Asymmetrex will deliver a talk on its first-in-class technologies for tissue stem ... 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):